Literature DB >> 23668898

Protease expression in giant cell tumour of bone: a comparative study on feline and human samples.

Leonardo Leonardi1, Irene Quattrini, Franco Roperto, Maria Serena Benassi.   

Abstract

Human giant cell tumour of bone (GCTB) is a rare low grade of malignancy tumour with tendency to recur. During tumourigenesis the bone remodeling balance is subverted by the tumour cellular components that interacting with bone matrix induce release of growth factors and cytokines, promoting cell proliferation and bone resorption. The master regulators of this positive feed-back are acid and neutral proteases that destroying extracellular matrix increase osteolysis. In contrast, in cats, very few data are reported on GCTB biological activity. In this study, histological features and metalloproteinase (MMPs) and urokinase plasminogen activator system (uPA) expression were compared in human and feline GCTB and differences in distribution and intensity related to histological pattern and clinical behaviour were determined. In both species, the overexpression of these molecules suggested a strong and complex cross-talk between tumour and microenvironment.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bone matrix; Cats; Giant cell tumour; Humans; Immunohistochemistry; Proteinases

Mesh:

Substances:

Year:  2013        PMID: 23668898     DOI: 10.1016/j.rvsc.2013.04.011

Source DB:  PubMed          Journal:  Res Vet Sci        ISSN: 0034-5288            Impact factor:   2.534


  6 in total

Review 1.  Prognosis of local recurrence in giant cell tumour of bone: what can we do?

Authors:  Yifeng He; Ji Zhang; Xiaoyi Ding
Journal:  Radiol Med       Date:  2017-03-07       Impact factor: 3.469

2.  Determination of urokinase-type plasminogen activator serum levels in healthy and oncologic cats.

Authors:  Cláudia Viegas; Augusto J de Matos; Liliana R Leite-Martins; Inês Viegas; Rui R F Ferreira; Hugo Gregório; Andreia A Santos
Journal:  Can J Vet Res       Date:  2020-01       Impact factor: 1.310

3.  Serum levels of urokinase-type plasminogen activator in healthy dogs and oncologic canine patients.

Authors:  Sofia C Ramos; Augusto J de Matos; João Niza Ribeiro; Liliana R Leite-Martins; Rui R F Ferreira; Inês Viegas; Andreia A Santos
Journal:  Vet World       Date:  2017-08-14

4.  Expression and activity of the urokinase plasminogen activator system in canine primary brain tumors.

Authors:  John H Rossmeisl; Kelli Hall-Manning; John L Robertson; Jamie N King; Rafael V Davalos; Waldemar Debinski; Subbiah Elankumaran
Journal:  Onco Targets Ther       Date:  2017-04-12       Impact factor: 4.147

5.  An unusual case of giant cell tumor of soft parts in an American Warmblood horse.

Authors:  Kurt Zimmerman; Frederic Almy; Geoff Saunders; Mark Crisman; Leonardo Leonardi
Journal:  Open Vet J       Date:  2019-02-26

6.  miR-106B-25 Cluster expression: a comparative human and canine osteosarcoma study.

Authors:  Leonardo Leonardi; Maria Serena Benassi; Serena Pollino; Carmen Locaputo; Laura Pazzaglia
Journal:  Vet Rec Open       Date:  2020-03-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.